Microparticle systems and their use for the treatment of multiple sclerosis
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsDorina Avram, Benjamin George Keselowsky, Joshua Stewart, Jonathan Joseph Cho
Life of this patent
Estimating the term…
Abstract
Provided are a dual microparticle system to treat Multiple Sclerosis, the system comprising phagocytosable and non-phagocytosable microparticles for delivery of at least one antigen, at least one immunomodulatory agent, at least one immunosuppressive agent and at least one chemoattractant to a subject suffering from Multiple Sclerosis to generate tolerogenic dendritic cells in the subject and treat the Multiple Sclerosis.
Claims16
A dual microparticle system for targeting an antigen-presenting immune cell in a subject who is suspected of having, at risk of having or has Multiple Sclerosis, wherein the microparticle system is a composition that comprises:
- microparticles that are phagocytosable by the antigen-presenting immune cell, and microparticles that are non-phagocytosable by the antigen-presenting immune cell;
- wherein the phagocytosable microparticles together comprise at least one myelin antigen, the at least one myelin antigen being an antigen involved in pathogenesis of multiple sclerosis, and at least one immunomodulatory agent selected from vitamin D3, vitamin D3 analog, glucocorticoid, estrogen, rapamycin, and retinoic acid;
- and wherein the non-phagocytosable microparticles comprise at least one immunosuppressive tolerogenic agent selected from IL-10, TGF-p, and nonsteroidal anti-inflammatory drugs (NSAIDs), an agent that recruits the antigen-presenting immune cell of interest selected from GM-CSF, G-CFS, M-CSF, CCL19, CCL20, CCL21, and VEGF-C, wherein the microparticle system further comprises a remyelinating agent selected from clemastine, clobetasol, digoxin, miconazole, phenytoin, and quetiapine.
A method of treating a subject who is suspected of having, at risk of having or has MS comprising administering a therapeutically effective amount of a first composition that comprises microparticles that are phagocytosable by the antigen-presenting immune cell, and a second composition comprising microparticles that are non-phagocytosable by the antigen-presenting immune cell;
- wherein the phagocytosable microparticles together comprise at least one myelin antigen, the at least one myelin antigen being an antigen involved in pathogenesis of multiple sclerosis and at least one immunomodulatory agent selected from vitamin D3, vitamin D3 analog, glucocorticoid, estrogen, rapamycin, and retinoic acid;
- wherein the non-phagocytosable microparticles comprise at least one immunosuppressive tolerogenic agent selected from IL-10, TGF-p, and nonsteroidal anti-inflammatory drugs (NSAIDs), an agent that recruits the antigen-presenting immune cell of interest selected from GM-CSF, G-CFS, M-CSF, CCL19, CCL20, CCL21, and VEGF-C;
- wherein and wherein the first composition and second composition are admixed prior administration or are administered separately.
Dependencies are inferred from the claim text.